Key facts
- Huvy’s last known valuation is $4.5M (Dec 2023).
- It has raised $780K; the latest was Early Stage VC in Oct 2025.
- Notable investors include Super Capital, ETEX Holdco, IMT Starter, Nouvelle Aquitaine Co-Investissement.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Huvy
- ·The full record, as it builds
Funding rounds
No funding rounds for Huvy are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Huvy
Developer of an artificial intelligence-based medical diagnostic system designed for the early detection of melanoma in clinical settings. The company's platform utilizes certified AI algorithms to assess the risk of pigmented skin lesions, offers CE IIb medical device compliance, enables urgent case triage, integrates with healthcare professionals' workflows, and provides patient guidance and follow-up, enabling healthcare providers to improve melanoma identification, optimize dermatology referral processes, and enhance patient safety and care accessibility.
- Sector
- Healthcare
- HQ
- Vaux-Sur-Mer, France
- Founded
- 2021
- Employees
- 9
- Website
- huvy.fr/
- Ownership
- Privately Held (backing)
Huvy doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Huvy shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Huvy in its N-PORT filings yet. We sweep new filings monthly.